Scholarlink

<p>Polycystic ovary syndrome (PCOS) is an endocrine and metabolic condition affecting reproductive health, marked by disrupted ovulation, excessive androgen levels, and impaired endometrial receptivity. Oxidative stress is an important part of its pathophysiological process. Atractylenolide III (ATIII), a major sesquiterpene lactone derived from <i>Atractylodes macrocephala</i> Koidz., exhibits antioxidant properties; however, its role and molecular mechanisms in PCOS have not yet been explored. A PCOS rat model was established using dehydroepiandrosterone (DHEA) and subsequently treated with ATIII or metformin. Estrous cycle, ovarian morphology, serum hormone levels, glucose metabolism, and endometrial receptivity markers were evaluated. Oxidative stress status was evaluated by detecting the levels of superoxide dismutase (SOD), malondialdehyde (MDA), and antioxidant-related genes and proteins expression. Ovarian transcriptomic sequencing was performed to explore potential molecular pathways associated with ATIII treatment. ATIII administration was associated with restoration of estrous cycle, reduction of cystic follicles, improvement of ovulation, and normalization of serum hormones and metabolic parameters in PCOS rats. Ovarian stromal fibrosis was attenuated, and morphological and molecular markers of endometrial receptivity were improved. ATIII treatment was accompanied by increased SOD activity, decreased MDA accumulation, and restoration of NRF2-related antioxidant genes and proteins. Transcriptomic analysis revealed enrichment of oxidative stress-related pathways, within which <i>Cybb</i> (encoding NOX2) was found as a differentially regulated gene that was upregulated in PCOS ovaries then reduced following ATIII treatment. ATIII improves reproductive and metabolic abnormalities and enhances endometrial receptivity in a PCOS rat model. These results are mediated by attenuation of ovarian oxidative stress and modulation of <i>Cybb</i>-related redox signaling. These data offer mechanistic insight into the pharmacological potential of ATIII in PCOS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Atractylenolide III improves ovarian dysfunction and endometrial receptivity in a PCOS rat model by regulating Cybb-mediated oxidative stress

  • 期刊论文

  • 发表日期：

    2026年3月30日

查看全文
  • Chunmei Bai,
  • Jianrong liu

摘要

Polycystic ovary syndrome (PCOS) is an endocrine and metabolic condition affecting reproductive health, marked by disrupted ovulation, excessive androgen levels, and impaired endometrial receptivity. Oxidative stress is an important part of its pathophysiological process. Atractylenolide III (ATIII), a major sesquiterpene lactone derived from Atractylodes macrocephala Koidz., exhibits antioxidant properties; however, its role and molecular mechanisms in PCOS have not yet been explored. A PCOS rat model was established using dehydroepiandrosterone (DHEA) and subsequently treated with ATIII or metformin. Estrous cycle, ovarian morphology, serum hormone levels, glucose metabolism, and endometrial receptivity markers were evaluated. Oxidative stress status was evaluated by detecting the levels of superoxide dismutase (SOD), malondialdehyde (MDA), and antioxidant-related genes and proteins expression. Ovarian transcriptomic sequencing was performed to explore potential molecular pathways associated with ATIII treatment. ATIII administration was associated with restoration of estrous cycle, reduction of cystic follicles, improvement of ovulation, and normalization of serum hormones and metabolic parameters in PCOS rats. Ovarian stromal fibrosis was attenuated, and morphological and molecular markers of endometrial receptivity were improved. ATIII treatment was accompanied by increased SOD activity, decreased MDA accumulation, and restoration of NRF2-related antioxidant genes and proteins. Transcriptomic analysis revealed enrichment of oxidative stress-related pathways, within which Cybb (encoding NOX2) was found as a differentially regulated gene that was upregulated in PCOS ovaries then reduced following ATIII treatment. ATIII improves reproductive and metabolic abnormalities and enhances endometrial receptivity in a PCOS rat model. These results are mediated by attenuation of ovarian oxidative stress and modulation of Cybb-related redox signaling. These data offer mechanistic insight into the pharmacological potential of ATIII in PCOS.